[
    [
        {
            "time": "2020-12-31",
            "original_text": "贝达药业：2020年度净利预增155%-185%",
            "features": {
                "keywords": [
                    "贝达药业",
                    "净利",
                    "预增",
                    "155%",
                    "185%"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "贝达药业：2020年度净利预增155%-185%",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-12-31",
            "original_text": "贝达药业(300558.SZ)预计2020年度归母净利润同比增长155.00%至185.00%",
            "features": {
                "keywords": [
                    "贝达药业",
                    "归母净利润",
                    "同比增长",
                    "155.00%",
                    "185.00%"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "贝达药业(300558.SZ)预计2020年度归母净利润同比增长155.00%至185.00%",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-12-31",
            "original_text": "贝达药业：2020年净利润同比预增155%至185%",
            "features": {
                "keywords": [
                    "贝达药业",
                    "净利润",
                    "同比预增",
                    "155%",
                    "185%"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "贝达药业：2020年净利润同比预增155%至185%",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-01-01",
            "original_text": "专访贝达药业丁列明：拓荒中国创新抗癌药，打造“非凡TKI”",
            "features": {
                "keywords": [
                    "贝达药业",
                    "丁列明",
                    "创新抗癌药",
                    "非凡TKI"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "专访贝达药业丁列明：拓荒中国创新抗癌药，打造“非凡TKI”",
                "Correlation": 7,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2020-11-01",
            "original_text": "港股IPO|贝达药业拟赴港上市，旗下肺癌国产新药已获批上市",
            "features": {
                "keywords": [
                    "贝达药业",
                    "港股IPO",
                    "肺癌国产新药",
                    "获批上市"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "港股IPO|贝达药业拟赴港上市，旗下肺癌国产新药已获批上市",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2020-12-31",
            "original_text": "2020年四季度基金医药持仓点评：四季度公募基金医药重仓持股小幅下降 头部聚集趋势延续",
            "features": {
                "keywords": [
                    "基金",
                    "医药持仓",
                    "公募基金",
                    "重仓持股",
                    "头部聚集"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "2020年四季度基金医药持仓点评：四季度公募基金医药重仓持股小幅下降 头部聚集趋势延续",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        }
    ]
]